What To Expect From Sanara MedTech Inc (SMTI) Q3 2025 Earnings

This article first appeared on GuruFocus.

Sanara MedTech Inc (NASDAQ:SMTI) is set to release its Q3 2025 earnings on Nov 12, 2025. The consensus estimate for Q3 2025 revenue is $26.63 million, and the earnings are expected to come in at -$0.22 per share. The full year 2025's revenue is expected to be $105.78 million, and the earnings are expected to be -$0.98 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 2 Warning Sign with SMTI.

Is SMTI fairly valued? Test your thesis with our free DCF calculator.

Over the past 90 days, revenue estimates for Sanara MedTech Inc (NASDAQ:SMTI) have increased from $104.27 million to $105.78 million for the full year 2025 and from $118.40 million to $121.05 million for 2026. Earnings estimates have also improved, rising from -$1.56 per share to -$0.98 per share for the full year 2025 and from -$1.39 per share to -$0.50 per share for 2026.

In the previous quarter ending on 2025-06-30, Sanara MedTech Inc's (NASDAQ:SMTI) actual revenue was $25.83 million, which beat analysts' revenue expectations of $25.15 million by 2.71%. Sanara MedTech Inc's (NASDAQ:SMTI) actual earnings were -$0.23 per share, which exceeded analysts' earnings expectations of -$0.44 per share by 47.73%. After releasing the results, Sanara MedTech Inc (NASDAQ:SMTI) was up by 16.20% in one day.

Based on the one-year price targets offered by 2 analysts, the average target price for Sanara MedTech Inc (NASDAQ:SMTI) is $50.00 with a high estimate of $54.00 and a low estimate of $46.00. The average target implies an upside of 75.62% from the current price of $28.47.

Based on GuruFocus estimates, the estimated GF Value for Sanara MedTech Inc (NASDAQ:SMTI) in one year is $59.85, suggesting an upside of 110.22% from the current price of $28.47.

Based on the consensus recommendation from 2 brokerage firms, Sanara MedTech Inc's (NASDAQ:SMTI) average brokerage recommendation is currently 2.0, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

Scroll to Top